RYBREVANT FASPRO™ Receives FDA Approval for First-Line EGFR-Mutated NSCLC
December 26, 2025
Brand Name :
Terlivaz
Synonyms :
terlipressin
Class :
Vasopressin-Related
Dosage Forms & Strengths
Injection
0.85mg/vial
Days 1-3: 0.85 mg slow IV bolus 4 times a day on day 1,2, and 3
Adjust dose based on serum creatinine (SCr) on day 4
0.85 mg IV 4 times a day if serum creatinine decreased by at least 30% from baseline
1.7 mg IV 4 times a day if serum creatinine decreased by <30% from baseline
Discontinue if SCr is at or above baseline
Continue terlipressin acetate for a maximum of 14 days or until 24 hours after two consecutive SCr 1.5 mg/dL values at least 2 hours apart
Adverse drug reactions
Frequency Defined
>10%
Abdominal pain (19.5%)
Respiratory failure (15.5%)
Diarrhea (13%)
Dyspnea (12.5%)
Nausea (16%)
1-10%
Bradycardia (5%)
Fluid overload (8.5%)
Ischemia-related events (4.5%)
Pleural effusion (5.5%)
Sepsis (5.5%)
Post marketing Reports
Hyponatremia
Headache
Pregnancy warnings:
US FDA pregnancy category: Not assigned
Lactation:
Excreted into human milk is unknown
Pregnancy Categories:
Category A: In the first or second trimester, well-controlled and satisfactory studies show no risk to the fetus.
Category B: Animal studies found no evidence of fetal risk, and there were not enough studies on pregnant women.
Category C: There was evidence of a risk of adverse effects in animal reproduction studies, but no adequate evidence in human studies.
Category D: adequate data available from various platforms with sufficient evidence of human fetal risk, but despite the potential risk, and only used in emergency cases for potential benefits
Category X: The risks of the drugs in this category outweigh the benefits. As a result, pregnant women should avoid these types of drugs.
Category N: There is no data available for the drug under this category
Patient Information Leaflet
Generic Name: terlipressin
Why do we use terlipressin?
terlipressin is a Vasopressin-Related used to treat Hepatorenal Syndrome.